We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RCUS market cap is 1.31B. The company's latest EPS is USD -3.3548 and P/E is -4.26.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 29M | 32M | 31M | 145M | 39M |
| Operating Income | -83M | -80M | -91M | 4M | -126M |
| Net Income | -75M | -71M | -81M | -4M | -93M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 15M | 77.52M | 382.88M | 112M | 117M |
| Operating Income | -89.91M | -124.85M | 54.25M | -280M | -340M |
| Net Income | -84.71M | -122.86M | 52.83M | -267M | -307M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.22B | 1.19B | 1.1B | 1.29B | 1.19B |
| Total Liabilities | 654M | 671M | 633M | 586M | 551M |
| Total Equity | 566M | 520M | 462M | 707M | 635M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 203.11M | 772.29M | 1.59B | 1.35B | 1.1B |
| Total Liabilities | 39.27M | 269.99M | 750.45M | 688M | 633M |
| Total Equity | 163.84M | 502.3M | 841.45M | 657M | 462M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -155M | -218M | -306M | -2M | -96M |
| Investing | 155M | 166M | 194M | -169M | -106M |
| Financing | 24M | 30M | 33M | 229M | 231M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -73.46M | 111.17M | -256.17M | 438M | -306M |
| Investing | 59.21M | -434.37M | -3.87M | -413M | 194M |
| Financing | 1.12M | 438.68M | 237.34M | 33M | 33M |
| Market Cap | 1.31B |
| Price to Earnings Ratio | -4.26 |
| Price to Sales Ratio | 11.17 |
| Price to Cash Ratio | 10.29 |
| Price to Book Ratio | 2.83 |
| Dividend Yield | - |
| Shares Outstanding | 91.51M |
| Average Volume (1 week) | 640.8k |
| Average Volume (1 Month) | 781.69k |
| 52 Week Change | 1.49% |
| 52 Week High | 20.31 |
| 52 Week Low | 13.495 |
| Spread (Intraday) | 0.77 (5.15%) |
| Company Name | Arcus Biosciences Inc |
| Address |
2140 s dupont hwy camden, delaware 19934 |
| Website | https://www.arcusbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
